225 related articles for article (PubMed ID: 36768723)
1. The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression-ALDH1A1, CD133, CD44-For Survival and Long-Term Follow-Up of Ovarian Cancer Patients.
Izycka N; Rucinski M; Andrzejewska M; Szubert S; Nowak-Markwitz E; Sterzynska K
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768723
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1).
Szafarowski T; Sierdziński J; Ludwig N; Głuszko A; Filipowska A; Szczepański MJ
Eur J Pharmacol; 2020 Jan; 867():172837. PubMed ID: 31811857
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of cancer stem cell markers, SALL4/ALDH1A1, is associated with tumor aggressiveness and poor survival in patients with serous ovarian carcinoma.
Sharbatoghli M; Shamshiripour P; Fattahi F; Kalantari E; Habibi Shams Z; Panahi M; Totonchi M; Asadi-Lari Z; Madjd Z; Saeednejad Zanjani L
J Ovarian Res; 2022 Jan; 15(1):17. PubMed ID: 35090523
[TBL] [Abstract][Full Text] [Related]
4. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
5. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.
Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
[TBL] [Abstract][Full Text] [Related]
8. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.
Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W
Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781
[TBL] [Abstract][Full Text] [Related]
9. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer.
Yamanaka T; Oshima T; Murayama D; Okamoto S; Matsui AI; Yasukawa M; Matsubara Y; Toda S; Hiroshima Y; Aoyama T; Suganuma N; Rino Y; Saito A; Miyagi Y; Iwasaki H; Yamashita T
Anticancer Res; 2023 May; 43(5):2145-2154. PubMed ID: 37097684
[TBL] [Abstract][Full Text] [Related]
12. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder.
Keymoosi H; Gheytanchi E; Asgari M; Shariftabrizi A; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(5):2013-20. PubMed ID: 24716927
[TBL] [Abstract][Full Text] [Related]
13. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
Steg AD; Bevis KS; Katre AA; Ziebarth A; Dobbin ZC; Alvarez RD; Zhang K; Conner M; Landen CN
Clin Cancer Res; 2012 Feb; 18(3):869-81. PubMed ID: 22142828
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J
BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355
[TBL] [Abstract][Full Text] [Related]
15. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.
Wang YC; Yo YT; Lee HY; Liao YP; Chao TK; Su PH; Lai HC
Am J Pathol; 2012 Mar; 180(3):1159-1169. PubMed ID: 22222226
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
17. CD44
Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact.
Tsunedomi R; Yoshimura K; Suzuki N; Hazama S; Nagano H
Surg Today; 2020 Dec; 50(12):1560-1577. PubMed ID: 32025858
[TBL] [Abstract][Full Text] [Related]
19. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A
Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663
[TBL] [Abstract][Full Text] [Related]
20. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
